PHAT
Phathom Pharmaceuticals, Inc.
Healthcare · Biotechnology · NMS
$10.74
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$856.6M
Trailing P/E
Forward P/E
7.46
Rev Growth
+104.4%
Profit Margin
-76.8%
ROE
Analyst Target
$25.50
Recommendation
STRONG BUY
About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue Ratio (0.00%)PASS
OverallPASS
Score Ethical: 64.7
Score Valuation: 78.5
Score Quality: 43.8
Score Combined: 47.8

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation85.0
Quality45.0
Cash Flow0.0
Moat40.0
Balance Sheet50.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: BRONZE · Score: 47.0 · Rank: #2680
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$1.2B
Price/Book
-2.43
Beta
0.567
Analysts
10
Total Revenue (TTM)
$204.9M
Total Debt
$547.2M
Rec. Mean
1.40
Short Ratio
7.34
Short % Float
0.1%
Employees
371

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 47.8 (P69 — top 31.3% of scored tickers). Unknown Moat. Ethical PASS. 10 analysts at Strong Buy.
Price: $10.74 | Target: $23.70 (+121%)
Score
48
Moat
Unknown
Conviction
Standard
Upside
+121%
The Fundamentals
Revenue Growth+104.4%
Profit Margin-76.8%
Forward P/E7.5
Market Cap$856.6M
Position Sizing Scenarios
Stop: $9.13 (-15%) | Entry: $10.74
SharesCostProfit to TargetR:R
To Consensus ($23.70, 10 analysts)
10$107.40+$129.60 (121%)8.0R
50$537.00+$648.00 (121%)8.0R
100$1,074.00+$1,296.00 (121%)8.0R
Risk Factors
  • Elevated short interest (7.34 days to cover)
The Verdict
Phathom Pharmaceuticals, Inc. passes all ethical screens, holds a unknown competitive moat, and is growing revenue at +104.4%.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
43.2
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-7.5%
worst expected daily loss, 19 in 20 days
CVaR 95%
-13.2%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.02
above 1.0 is good
Max Drawdown
-88.3%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
70
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
DEATH_CROSS
Bollinger Position
BELOW_LOWER
Beta
Relative Volume
0.4x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
ARKG0.305
RXRX0.302
URGN0.298
IMTX0.286
ARKK0.278
Inverse Correlated
TickerCorrelation
ATO.PA-0.183
IIJIY-0.146
LPTVQ-0.140
KR-0.134
4337.SR-0.124
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Friday
Worst Day
Monday
Best Month
Jun
Worst Month
Nov
Fri-Mon Effect
0.7952899163143026
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-8.9%
3M Return
-23.9%
6M Return
-30.4%
12M Return
+150.5%
Momentum Rank
#2981
Momentum Signal
FLAT

Get our daily market read free. Join thousands of traders.

Free Explorer Access